SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2012
ELI LILLY AND COMPANY
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
Lilly Corporate Center
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants telephone number, including area code: (317) 276-2000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 5.02 Election of Director.
The Board of Directors of Eli Lilly and Company elected William G. Kaelin, Jr., M.D., as a new member, effective June 4, 2012. Dr. Kaelin, 54, is a Professor in the Department of Medicine at Dana-Farber Cancer Institute and Brigham and Womens Hospital, Senior Physician at Brigham and Womens Hospital, and Associate Director, Basic Science, at the Dana-Farber/Harvard Cancer Center. As a member of Lillys board, Dr. Kaelin will serve on the science and technology committee and the finance committee. He will serve under interim election to fill a vacancy left by the retirement of Dr. Martin Feldstein and will stand for election by Lilly shareholders at the companys annual meeting in May, 2014.
Dr. Kaelin received his medical degree from Duke University in 1982 and was a house officer in internal medicine at Johns Hopkins Hospital. He went on to become a medical oncology clinical fellow at the Dana-Farber Cancer Institute and a postdoctoral fellow in the laboratory of Dr. David Livingston. He became an independent investigator at Dana-Farber Cancer Institute in 1992 as a James S. McDonnell Scholar and became a Howard Hughes Medical Institute investigator in 1998.
Dr. Kaelin is an elected member of the Institute of Medicine and the National Academy of Sciences and has served on numerous boards and committees, including the American Association for Cancer Researchs Board of Directors and the National Cancer Institute Board of Scientific Advisors. He has received many awards for his work, including the Canada Gairdner International Prize, the AACR-Richard and Hinda Rosenthal Prize for Cancer Research, and the Paul Marks Prize for Cancer Research from Memorial Sloan-Kettering Cancer Center. Most recently, he was named co-recipient of the Scientific Grand Prize 2012 of the Lefoulon-Delalande Foundation.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
|By:||/s/ James B. Lootens|
|Name:||James B. Lootens|
Secretary and Deputy
Dated: June 4, 2012